1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
Certification and Notice of Termination of Registration
under Section 12(g) of the Securities Exchange Act of 1934
or Suspension of Duty to File Reports Under Sections 13(d)
and 15(d) of the Securities Exchange Act of 1934
Commission File No. 01-9723
-------------
Pharmaceutical Marketing Services Inc.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Pharmaceutical Marketing Services Inc.
45 Rockefeller Plaza
Suite 912
New York, New York 10111
(212) 841-0610
- --------------------------------------------------------------------------------
(Address, including zip code and telephone number, including
area code, of Registrant's principal executive offices)
Common Stock, par value $.01 per share
- --------------------------------------------------------------------------------
(Title of each class of securities covered by this Form)
None
- --------------------------------------------------------------------------------
(Titles of all other classes of securities for which a duty
to file reports under Section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i) /X/ Rule 12h-3(b)(1)(ii) / /
Rule 12g-4(a)(1)(ii) / / Rule 12h-3(b)(2)(i) / /
Rule 12g-4(a)(2)(i) / / Rule 12h-3(b)(2)(ii) / /
Rule 12g-4(a)(2)(ii) / / Rule 15d-6 / /
Rule 12h-3(b)(1)(i) /X/
Approximate number of holders of record as of the certification or
notice date: One
--------------------
Pursuant to the requirements of the Securities Exchange Act of 1934,
Quintiles-Scott Levin, Inc., successor to Pharmaceutical Marketing Services
Inc., has caused this certification/notice to be signed on its behalf by the
undersigned duly authorized person.
Dated: March 30, 1999 By: /s/ James L. Bierman
----------------- -------------------------------
James L. Bierman
Vice President